Diagnosis and treatment of bronchopulmonary neuroendocrine tumours: State of the art

References

• Rekhtman N. Neuroendocrine tumors of the lung: An update. Arch Pathol Lab Med 2010;134:1628–38.
   PubMed Web of Science ®Google Scholar
• Fisseler-Eckhoff A, Demes M. Neuroendocrine tumors of the lung. Cancers (Basel) 2012;4:777–98.
   PubMedGoogle Scholar
• Travis WD, Bramilla E, Burke AP, Marx A, Nicholson AG. Pathology and genetics of tumours of the lung, pleura, thymus and heart. World Health classification of tumours, 4th ed. Lyon: IARC Press; 2015.
   Google Scholar
• Referenceprogram. Dansk Lunge Cancer Gruppe. Available from: http://www.lungecancer.dk/documents/BB655853-A6AB-4D15-8741-F5100FFB0247.pdf [cited 2015 Jun 12].
   Google Scholar
• Kulke MH, Shah MH, Benson AB, 3rd, Bergsland E, Berlin JD, Blaszkowsky LS, et al. Neuroendocrine tumors, version 1.2015. J Natl Compr Canc Netw 2015;13:78–108.
   PubMed Web of Science ®Google Scholar
• Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, et al. Non-small cell lung cancer, version 1.2015. J Natl Compr Canc Netw 2014;12:1738–61.
   Web of Science ®Google Scholar
• Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after “carcinoid”: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063–72.
   PubMed Web of Science ®Google Scholar
• Travis WD, Rush W, Flieder DB, Falk R, Fleming MV, Gal AA, et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 1998;22:934–44.
   PubMed Web of Science ®Google Scholar
• Phan AT, Oberg K, Choi J, Harrison LH, Jr, Hassan MM, Strosberg JR, et al. NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: Well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus). Pancreas 2010;39:784–98.
   PubMed Web of Science ®Google Scholar
• Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 2011;40:1–18, vii.
   PubMed Web of Science ®Google Scholar
• Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: A review of nomenclature, grading, and staging systems. Pancreas 2010;39:707–12.
   PubMed Web of Science ®Google Scholar
• Moran CA, Suster S, Coppola D, Wick MR. Neuroendocrine carcinomas of the lung: A critical analysis. Am J Clin Pathol 2009;131:206–21.
   PubMed Web of Science ®Google Scholar
• Goldstraw P. The 7th edition of TNM in lung cancer: What now? J Thorac Oncol 2009;4:671–3.
   PubMed Web of Science ®Google Scholar
• Travis WD, Giroux DJ, Chansky K, Crowley J, Asamura H, Brambilla E, et al. The IASLC Lung Cancer Staging Project: Proposals for the inclusion of broncho-pulmonary carcinoid tumors in the forthcoming (seventh) edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2008;3:1213–23.
   PubMed Web of Science ®Google Scholar
• Travis WD. Advances in neuroendocrine lung tumors. Ann Oncol 2010;21(Suppl 7):vii65–71.
   Google Scholar
• Janson ET, Sorbye H, Welin S, Federspiel B, Gronbaek H, Hellman P, et al. Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Acta Oncol 2014;53:1284–97.
   PubMed Web of Science ®Google Scholar
• Pelosi G, Rodriguez J, Viale G, Rosai J. Typical and atypical pulmonary carcinoid tumor overdiagnosed as small-cell carcinoma on biopsy specimens: A major pitfall in the management of lung cancer patients. Am J Surg Pathol 2005;29:179–87.
   PubMed Web of Science ®Google Scholar
• Rindi G, Klersy C, Inzani F, Fellegara G, Ampollini L, Ardizzoni A, et al. Grading the neuroendocrine tumors of the lung: An evidence-based proposal. Endocr Relat Cancer 2013;21:1–16.
   PubMed Web of Science ®Google Scholar
• Warth A, Fink L, Fisseler-Eckhoff A, Jonigk D, Keller M, Ott G, et al. Interobserver agreement of proliferation index (Ki-67) outperforms mitotic count in pulmonary carcinoids. Virchows Arch 2013;462:507–13.
   PubMed Web of Science ®Google Scholar
• Ladekarl M. Objective malignancy grading: A review emphasizing unbiased stereology applied to breast tumors. APMIS Suppl 1998;79:1–34.
   PubMedGoogle Scholar
• Pelosi G, Rindi G, Travis WD, Papotti M. Ki-67 antigen in lung neuroendocrine tumors: Unraveling a role in clinical practice. J Thorac Oncol 2014;9:273–84.
   PubMed Web of Science ®Google Scholar
• Nassar AA, Jaroszewski DE, Helmers RA, Colby TV, Patel BM, Mookadam F. Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: A systematic overview. Am J Respir Crit Care Med 2011;184:8–16.
   PubMed Web of Science ®Google Scholar
• Ferolla P, Daddi N, Urbani M, Semeraro A, Ribacchi R, Giovenali P, et al. Tumorlets, multicentric carcinoids, lymph-nodal metastases, and long-term behavior in bronchial carcinoids. J Thorac Oncol 2009;4:383–7.
   PubMed Web of Science ®Google Scholar
• Seregni E, Ferrari L, Bajetta E, Martinetti A, Bombardieri E. Clinical significance of blood chromogranin A measurement in neuroendocrine tumours. Ann Oncol 2001;12(Suppl 2):S69–72.
   Google Scholar
• Bajetta E, Ferrari L, Martinetti A, Celio L, Procopio G, Artale S, et al. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer 1999;86:858–65.
   PubMed Web of Science ®Google Scholar
• Gustafsson BI, Kidd M, Chan A, Malfertheiner MV, Modlin IM. Bronchopulmonary neuroendocrine tumors. Cancer 2008;113:5–21.
   PubMed Web of Science ®Google Scholar
• Bini A, Brandolini J, Cassanelli N, Davoli F, Dolci G, Sellitri F, et al. Typical and atypical pulmonary carcinoids: Our institutional experience. Interact Cardiovasc Thorac Surg 2008;7:415–8.
   PubMedGoogle Scholar
• Armengol G, Sarhadi VK, Ronty M, Tikkanen M, Knuuttila A, Knuutila S. Driver gene mutations of non-small-cell lung cancer are rare in primary carcinoids of the lung: NGS study by Ion Torrent. Lung 2015;193:303–8.
   PubMed Web of Science ®Google Scholar
• Pieterman CR, Conemans EB, Dreijerink KM, de Laat JM, Timmers HT, Vriens MR, et al. Thoracic and duodenopancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1: Natural history and function of menin in tumorigenesis. Endocr Relat Cancer 2014;21: R121–42.
   Google Scholar
• Marx SJ. Molecular genetics of multiple endocrine neoplasia types 1 and 2. Nat Rev Cancer 2005;5:367–75.
   PubMed Web of Science ®Google Scholar
• Gollard R, Jhatakia S, Elliott M, Kosty M. Large cell/ neuroendocrine carcinoma. Lung Cancer 2010;69:13–8.
   PubMed Web of Science ®Google Scholar
• Kaltsas G, Androulakis II, de Herder WW, Grossman AB. Paraneoplastic syndromes secondary to neuroendocrine tumours. Endocr Relat Cancer 2010;17:R173–93.
   PubMed Web of Science ®Google Scholar
• Oberg K, Hellman P, Ferolla P, Papotti M, ESMO Guidelines Working Group. Neuroendocrine bronchial and thymic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(Suppl 7): vii120–3.
   PubMedGoogle Scholar
• Jensen RT, Berna MJ, Bingham DB, Norton JA. Inherited pancreatic endocrine tumor syndromes: Advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer 2008;113(7 Suppl):1807–43.
   PubMed Web of Science ®Google Scholar
• Multipel Endokrin Neoplasi.Klaringsrapport. 2011. Available from: http://www.endocrinology.dk/Multipel%20endokrin%20neoplasi%20_2_.pdf [cited 2015 Jun 12].
   Google Scholar
• Patel C, Mathur M, Escarcega RO, Bove AA. Carcinoid heart disease: Current understanding and future directions. Am Heart J 2014;167:789–95.
   PubMed Web of Science ®Google Scholar
• Alexandraki KI, Grossman AB. The ectopic ACTH syndrome. Rev Endocr Metab Disord 2010;11:117–26.
   PubMed Web of Science ®Google Scholar
• Detterbeck FC, Lewis SZ, Diekemper R, Addrizzo-Harris D, Alberts WM. Executive summary: Diagnosis and management of lung cancer, 3rd ed. American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013;143(5 Suppl):7S–37S.
   Google Scholar
• Detterbeck FC. Management of carcinoid tumors. Ann Thorac Surg 2010;89:998–1005.
   PubMed Web of Science ®Google Scholar
• De Leyn P, Dooms C, Kuzdzal J, Lardinois D, Passlick B, Rami-Porta R, et al. Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer. Eur J Cardiothorac Surg 2014;45:787–98.
   PubMed Web of Science ®Google Scholar
• Vilmann P, Clementsen PF, Colella S, Siemsen M, De Leyn P, Dumonceau JM, et al. Combined endobronchial and esophageal endosonography for the diagnosis and staging of lung cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline, in cooperation with the European Respiratory Society (ERS) and the European Society of Thoracic Surgeons (ESTS). Endoscopy 2015;47:545–59.
   PubMed Web of Science ®Google Scholar
• Luckraz H, Amer K, Thomas L, Gibbs A, Butchart EG. Long-term outcome of bronchoscopically resected endobronchial typical carcinoid tumors. J Thorac Cardiovasc Surg 2006;132:113–5.
   PubMed Web of Science ®Google Scholar
• Brokx HA, Paul MA, Postmus PE, Sutedja TG. Long-term follow-up after first-line bronchoscopic therapy in patients with bronchial carcinoids. Thorax 2015;70:468–72.
   PubMed Web of Science ®Google Scholar
• Escalon J, Detterbeck F. Carcinoid tumors. In: Shielsd T, LoCisero JI, Reed C, Feins R. General thoracic surgery, 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2009. p 1539–54.
   Google Scholar
• Filosso PL, Guerrera F, Evangelista A, Welter S, Thomas P, Casado PM, et al. Prognostic model of survival for typical bronchial carcinoid tumours: Analysis of 1109 patients on behalf of the European Society of Thoracic Surgeons (ESTS) Neuroendocrine Tumours Working Groupdagger. Eur J Cardiothorac Surg Epub 2015 Jan 5.
   Google Scholar
• Binderup T, Knigge U, Loft A, Federspiel B, Kjaer A. 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res 2010;16:978–85.
   PubMed Web of Science ®Google Scholar
• Kayani I, Conry BG, Groves AM, Win T, Dickson J, Caplin M, et al. A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors. J Nucl Med 2009;50:1927–32.
   PubMed Web of Science ®Google Scholar
• Stefani A, Franceschetto A, Nesci J, Aramini B, Proli C, Kaleci S, et al. Integrated FDG-PET/CT imaging is useful in the approach to carcinoid tumors of the lung. J Cardiothorac Surg 2013;8:223–8090–8–223.
   PubMed Web of Science ®Google Scholar
• Daniels CE, Lowe VJ, Aubry MC, Allen MS, Jett JR. The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules. Chest 2007;131:255–60.
   PubMed Web of Science ®Google Scholar
• Jindal T, Kumar A, Venkitaraman B, Meena M, Kumar R, Malhotra A, et al. Evaluation of the role of [18F]FDG-PET/CT and [68Ga]DOTATOC-PET/CT in differentiating typical and atypical pulmonary carcinoids. Cancer Imaging 2011;11:70–5.
   PubMed Web of Science ®Google Scholar
• Moore W, Freiberg E, Bishawi M, Halbreiner MS, Matthews R, Baram D, et al. FDG-PET imaging in patients with pulmonary carcinoid tumor. Clin Nucl Med 2013;38:501–5.
   PubMed Web of Science ®Google Scholar
• Lococo F, Cesario A, Paci M, Filice A, Versari A, Rapicetta C, et al. PET/CT assessment of neuroendocrine tumors of the lung with special emphasis on bronchial carcinoids. Tumour Biol 2014;35:8369–77.
   PubMed Web of Science ®Google Scholar
• Treglia G, Castaldi P, Rindi G, Giordano A, Rufini V. Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: A meta-analysis. Endocrine 2012;42:80–7.
   PubMed Web of Science ®Google Scholar
• Oberg K. Molecular imaging radiotherapy: Theranostics for personalized patient management of neuroendocrine tumors (NETs). Theranostics 2012;2:448–58.
   PubMed Web of Science ®Google Scholar
• Pfeifer A, Knigge U, Binderup T, Mortensen J, Oturai P, Loft A, et al. 64Cu-DOTATATE PET for neuroendocrine tumors: A prospective head-to-head comparison with 111In-DTPA-octreotide in 112 patients. J Nucl Med Epub 2015 May 7.
   Google Scholar
• Kayani I, Bomanji JB, Groves A, Conway G, Gacinovic S, Win T, et al. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG. Cancer 2008;112: 2447–55.
   PubMed Web of Science ®Google Scholar
• Lococo F, Perotti G, Cardillo G, De Waure C, Filice A, Graziano P, et al. Multicenter comparison of 18F-FDG and 68Ga-DOTA-peptide PET/CT for pulmonary carcinoid. Clin Nucl Med 2015;40:e183–9.
   Google Scholar
• Ducrocq X, Thomas P, Massard G, Barsotti P, Giudicelli R, Fuentes P, et al. Operative risk and prognostic factors of typical bronchial carcinoid tumors. Ann Thorac Surg 1998;65:1410–4.
   PubMed Web of Science ®Google Scholar
• Oxford Centre for Evidence-based Medicine Levels of Evidence and Grades of Recommendations. 2009. Available from: http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009. [cited 2015 Jun 12].
   Google Scholar
• Caplin ME, Baudin E, Ferolla P, Filosso P, Garcia-Yuste M, Lim E, et al. Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society Expert Consensus and Recommendations for Best Practice for Typical and Atypical Pulmonary Carcinoid. Ann Oncol Epub 2015 Feb 2.
   Google Scholar
• Deslauriers J, Gregoire J, Jacques LF, Piraux M, Guojin L, Lacasse Y. Sleeve lobectomy versus pneumonectomy for lung cancer: A comparative analysis of survival and sites or recurrences. Ann Thorac Surg 2004;77:1152–6; discussion 1156.
   PubMed Web of Science ®Google Scholar
• Fernandez FG, Battafarano RJ. Large-cell neuroendocrine carcinoma of the lung: An aggressive neuroendocrine lung cancer. Semin Thorac Cardiovasc Surg 2006;18:206–10.
   PubMedGoogle Scholar
• Garcia-Yuste M, Matilla JM, Cueto A, Paniagua JM, Ramos G, Canizares MA, et al. Typical and atypical carcinoid tumours: Analysis of the experience of the Spanish Multi-centric Study of Neuroendocrine Tumours of the Lung. Eur J Cardiothorac Surg 2007;31:192–7.
   PubMed Web of Science ®Google Scholar
• Naalsund A, Rostad H, Strom EH, Lund MB, Strand TE. Carcinoid lung tumors – incidence, treatment and outcomes: A population-based study. Eur J Cardiothorac Surg 2011;39:565–9.
   PubMed Web of Science ®Google Scholar
• Filosso PL, Ruffini E, Di Gangi S, Guerrera F, Bora G, Ciccone G, et al. Prognostic factors in neuroendocrine tumours of the lung: A single-centre experience. Eur J Cardiothorac Surg 2014;45:521–6; discussion 526.
   PubMed Web of Science ®Google Scholar
• Cardillo G, Sera F, Di Martino M, Graziano P, Giunti R, Carbone L, et al. Bronchial carcinoid tumors: Nodal status and long-term survival after resection. Ann Thorac Surg 2004;771781–5.
   Google Scholar
• Iyoda A, Hiroshima K, Moriya Y, Iwadate Y, Takiguchi Y, Uno T, et al. Postoperative recurrence and the role of adjuvant chemotherapy in patients with pulmonary large-cell neuroendocrine carcinoma. J Thorac Cardiovasc Surg 2009;138:446–53.
   PubMed Web of Science ®Google Scholar
• Sarkaria IS, Iyoda A, Roh MS, Sica G, Kuk D, Sima CS, et al. Neoadjuvant and adjuvant chemotherapy in resected pulmonary large cell neuroendocrine carcinomas: A single institution experience. Ann Thorac Surg 2011;92:1180–6; discussion 1186–7.
   PubMed Web of Science ®Google Scholar
• Takei H, Asamura H, Maeshima A, Suzuki K, Kondo H, Niki T, et al. Large cell neuroendocrine carcinoma of the lung: A clinicopathologic study of eighty-seven cases. J Thorac Cardiovasc Surg 2002;124:285–92.
   PubMed Web of Science ®Google Scholar
• Fournel L, Falcoz PE, Alifano M, Charpentier MC, Boudaya MS, Magdeleinat P, et al. Surgical management of pulmonary large cell neuroendocrine carcinomas: A 10-year experience. Eur J Cardiothorac Surg 2013;43:111–4.
   PubMed Web of Science ®Google Scholar
• Filosso PL, Rena O, Guerrera F, Moreno Casado P, Sagan D, Raveglia F, et al. Clinical management of atypical carcinoid and large-cell neuroendocrine carcinoma: A multicentre study on behalf of the European Society of Thoracic Surgeons (ESTS) Neuroendocrine Tumours of the Lung Working Groupdagger. Eur J Cardiothorac Surg 2015;48: 55–64.
   PubMed Web of Science ®Google Scholar
• Filosso PL, Ferolla P, Guerrera F, Ruffini E, Travis WD, Rossi G, et al. Multidisciplinary management of advanced lung neuroendocrine tumors. J Thorac Dis 2015;7(Suppl 2):S163
   Google Scholar
• Whitson BA, Groth SS, Duval SJ, Swanson SJ, Maddaus MA. Surgery for early-stage non-small cell lung cancer: A systematic review of the video-assisted thoracoscopic surgery versus thoracotomy approaches to lobectomy. Ann Thorac Surg 2008;86:2008–16; discussion 2016–8.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhang Y, Feng H, Yao Z, Teng J, Wei D, et al. Is video-assisted thoracic surgery lobectomy better than thoracotomy for early-stage non-small-cell lung cancer? A systematic review and meta-analysis. Eur J Cardiothorac Surg 2013;44:407–14.
   PubMed Web of Science ®Google Scholar
• Anile M, Diso D, Rendina EA, Venuta F. Bronchoplastic procedures for carcinoid tumors. Thorac Surg Clin 2014; 24:299–303.
   PubMed Web of Science ®Google Scholar
• DOLG's Radioterapigruppes Rekommandationer for Udførelse af strålebehandling ved lungekræft. 2014 Available from: http://www.dolg.dk/pdf/rekommandationer.pdf [cited 2015 Jun 12].
   Google Scholar
• Nussbaum DP, Speicher PJ, Gulack BC, Hartwig MG, Onaitis MW, D’Amico TA, et al. Defining the role of adjuvant chemotherapy after lobectomy for typical bronchopulmonary carcinoid tumors. Ann Thorac Surg 2015;99:428–34.
   PubMed Web of Science ®Google Scholar
• Mackley HB, Videtic GM. Primary carcinoid tumors of the lung: A role for radiotherapy. Oncology (Williston Park) 2006;20:1537–43; discussion 1544–5, 1549.
   PubMed Web of Science ®Google Scholar
• Wirth LJ, Carter MR, Janne PA, Johnson BE. Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy. Lung Cancer 2004; 44:213–20.
   PubMed Web of Science ®Google Scholar
• Kaplan B, Stevens CW, Allen P, Liao Z, Komaki R. Outcomes and patterns of failure in bronchial carcinoid tumors. Int J Radiat Oncol Biol Phys 2003;55:125–31.
   PubMed Web of Science ®Google Scholar
• Skuladottir H, Hirsch FR, Hansen HH, Olsen JH. Pulmonary neuroendocrine tumors: Incidence and prognosis of histological subtypes. A population-based study in Denmark. Lung Cancer 2002;37:127–35.
   Google Scholar
• Martin-Richard M, Massuti B, Pineda E, Alonso V, Marmol M, Castellano D, et al. Antiproliferative effects of lanreotide autogel in patients with progressive, well- differentiated neuroendocrine tumours: A Spanish, multicentre, open-label, single arm phase II study. BMC Cancer 2013;13:427–2407–13–427.
   PubMed Web of Science ®Google Scholar
• Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group. J Clin Oncol 2009;27:4656–63.
   PubMed Web of Science ®Google Scholar
• Filosso PL, Ruffini E, Oliaro A, Papalia E, Donati G, Rena O. Long-term survival of atypical bronchial carcinoids with liver metastases, treated with octreotide. Eur J Cardiothorac Surg 2002;21:913–7.
   PubMed Web of Science ®Google Scholar
• Caplin ME, Pavel M, Cwikla JB, Phan AT, Raderer M, Sedlackova E, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 2014;371:224–33.
   PubMed Web of Science ®Google Scholar
• Modlin IM, Pavel M, Kidd M, Gustafsson BI. Review article: Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther 2010;31:169–88.
   PubMed Web of Science ®Google Scholar
• Volante M, Brizzi MP, Faggiano A, La Rosa S, Rapa I, Ferrero A, et al. Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: A proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol 2007;20:1172–82.
   PubMed Web of Science ®Google Scholar
• Binderup T, Knigge U, Mellon Mogensen A, Palnaes Hansen C, Kjaer A. Quantitative gene expression of somatostatin receptors and noradrenaline transporter underlying scintigraphic results in patients with neuroendocrine tumors. Neuroendocrinology 2008;87:223–32.
   PubMed Web of Science ®Google Scholar
• Righi L, Volante M, Tavaglione V, Bille A, Daniele L, Angusti T, et al. Somatostatin receptor tissue distribution in lung neuroendocrine tumours: A clinicopathologic and immunohistochemical study of 218 ‘clinically aggressive’ cases. Ann Oncol 2010;21:548–55.
   PubMed Web of Science ®Google Scholar
• Pavel ME, Hainsworth JD, Baudin E, Peeters M, Horsch D, Winkler RE, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): A randomised, placebo-controlled, phase 3 study. Lancet 2011;378:2005–12.
   PubMed Web of Science ®Google Scholar
• Bajetta E, Catena L, Fazio N, Pusceddu S, Biondani P, Blanco G, et al. Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: An ITMO group study. Cancer 2014;120:2457–63.
   PubMed Web of Science ®Google Scholar
• Fazio N, Granberg D, Grossman A, Saletan S, Klimovsky J, Panneerselvam A, et al. Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: Analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study. Chest 2013;143:955–62.
   PubMed Web of Science ®Google Scholar
• Anthony LB, Pavel ME, Hainsworth JD, Kvols LK, Segal S, Horsch D, et al. Impact of previous somatostatin analogue use on the activity of everolimus in patients with advanced neuroendocrine tumors: Analysis from the phase III RADIANT-2 Trial. Neuroendocrinology Epub 2015 Mar 21.
   Google Scholar
• Kolby L, Persson G, Franzen S, Ahren B. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. Br J Surg 2003;90:687–93.
   PubMed Web of Science ®Google Scholar
• Arnold R, Rinke A, Klose KJ, Muller HH, Wied M, Zamzow K, et al. Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: A randomized trial. Clin Gastroenterol Hepatol 2005;3: 761–71.
   PubMed Web of Science ®Google Scholar
• Faiss S, Pape UF, Bohmig M, Dorffel Y, Mansmann U, Golder W, et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors – the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 2003;21:2689–96.
   PubMed Web of Science ®Google Scholar
• Sun W, Lipsitz S, Catalano P, Mailliard JA, Haller DG, Eastern Cooperative Oncology Group. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol 2005;23:4897–904.
   PubMed Web of Science ®Google Scholar
• Turner NC, Strauss SJ, Sarker D, Gillmore R, Kirkwood A, Hackshaw A, et al. Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. Br J Cancer 2010;102:1106–12.
   PubMed Web of Science ®Google Scholar
• Weatherstone K, Meyer T. Streptozocin-based chemotherapy is not history in neuroendocrine tumours. Target Oncol 2012;7:161–8.
   PubMed Web of Science ®Google Scholar
• Moertel CG, Kvols LK, O’Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991;68:227–32.
   PubMed Web of Science ®Google Scholar
• Mitry E, Baudin E, Ducreux M, Sabourin JC, Rufie P, Aparicio T, et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 1999;81:1351–5.
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Spigel DR, Litchy S, Greco FA. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: A Minnie Pearl Cancer Research Network Study. J Clin Oncol 2006;24:3548–54.
   PubMed Web of Science ®Google Scholar
• Tatar Z, Thivat E, Planchat E, Gimbergues P, Gadea E, Abrial C, et al. Temozolomide and unusual indications: Review of literature. Cancer Treat Rev 2013;39: 125–35.
   PubMed Web of Science ®Google Scholar
• Crona J, Fanola I, Lindholm DP, Antonodimitrakis P, Oberg K, Eriksson B, et al. Effect of temozolomide in patients with metastatic bronchial carcinoids. Neuroendocrinology 2013;98:151–5.
   PubMed Web of Science ®Google Scholar
• Spada F, Fumagali C, Antonuzzo L, Messerini L, Radice D, Di Rocco R, et al. Capacetabin plus temozolomide (CAP-TEM) in patients with advanced neuroendocrine neoplasm (NEN): An Italian multicentral retrospective analysis. J Clin Oncol 2014;32(Suppl 3;abstr 281).
   Web of Science ®Google Scholar
• Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT, et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011;117:268–75.
   PubMed Web of Science ®Google Scholar
• Ekeblad S, Sundin A, Janson ET, Welin S, Granberg D, Kindmark H, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 2007;13:2986–91.
   PubMed Web of Science ®Google Scholar
• Welin S, Sorbye H, Sebjornsen S, Knappskog S, Busch C, Oberg K. Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer 2011;117: 4617–22.
   PubMed Web of Science ®Google Scholar
• Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006;24:401–6.
   PubMed Web of Science ®Google Scholar
• Koumarianou A, Kaltsas G. Bevacizumab plus temozolomide: A novel treatment option for advanced neuroendocrine tumors? J Clin Oncol 2013;31:975–6.
   PubMed Web of Science ®Google Scholar
• Koumarianou A, Antoniou S, Kanakis G, Economopoulos N, Rontogianni D, Ntavatzikos A, et al. Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours. Endocr Relat Cancer 2012;19:L1–4.
   PubMed Web of Science ®Google Scholar
• Chan JA, Stuart K, Earle CC, Clark JW, Bhargava P, Miksad R, et al. Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol 2012;30:2963–8.
   PubMed Web of Science ®Google Scholar
• Yang Z, Tang LH, Klimstra DS. Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well- differentiated neuroendocrine tumors metastatic to the liver: Implications for prognostic stratification. Am J Surg Pathol 2011;35:853–60.
   PubMed Web of Science ®Google Scholar
• van Essen M, Krenning EP, Bakker WH, de Herder WW, van Aken MO, Kwekkeboom DJ. Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin. Eur J Nucl Med Mol Imaging 2007;34: 1219–27.
   PubMed Web of Science ®Google Scholar
• van Essen M, Krenning EP, Kam BL, de Herder WW, Feelders RA, Kwekkeboom DJ. Salvage therapy with (177)Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors. J Nucl Med 2010;51: 383–90.
   PubMed Web of Science ®Google Scholar
• Pfeifer AK, Gregersen T, Gronbaek H, Hansen CP, Muller-Brand J, Herskind Bruun K, et al. Peptide receptor radionuclide therapy with Y-DOTATOC and (177)Lu- DOTATOC in advanced neuroendocrine tumors: Results from a Danish cohort treated in Switzerland. Neuroendocrinology 2011;93:189–96.
   PubMed Web of Science ®Google Scholar
• Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol 2011;29:2416–23.
   PubMed Web of Science ®Google Scholar
• Bison SM, Konijnenberg MW, Melis M, Pool SE, Bernsen MR, Teunissen JJ, et al. Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: Focus on future developments. Clin Transl Imaging 2014;2:55–66.
   PubMedGoogle Scholar
• Forrer F, Uusijarvi H, Storch D, Maecke HR, Mueller-Brand J. Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC. J Nucl Med 2005;46:1310–6.
   PubMed Web of Science ®Google Scholar
• Zatelli MC, Minoia M, Martini C, Tagliati F, Ambrosio MR, Schiavon M, et al. Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids. Endocr Relat Cancer 2010;17:719–29.
   PubMed Web of Science ®Google Scholar
• Johnbeck CB, Munk Jensen M, Haagen Nielsen C, Fisker Hag AM, Knigge U, Kjaer A. 18F-FDG and 18F-FLT-PET imaging for monitoring everolimus effect on tumor-growth in neuroendocrine tumors: Studies in human tumor xenografts in mice. PLoS One 2014;9:e91387.
   Google Scholar
• Pavel ME. RAMSETE: A single-arm, multicenter, single-stage phase II trial of RAD001 (everolimus) in advanced and metastatic silent neuro-endocrine tumours in Europe. J Clin Oncol 2012;30(Suppl;abstr 4122).
   Web of Science ®Google Scholar
• Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: Results of a phase II study. J Clin Oncol 2008;26:4311–8.
   PubMed Web of Science ®Google Scholar
• Lewis MA, Hobday TJ. Treatment of neuroendocrine tumor liver metastases. Int J Hepatol 2012;2012:973946.
   PubMedGoogle Scholar
• Glazer ES, Tseng JF, Al-Refaie W, Solorzano CC, Liu P, Willborn KA, et al. Long-term survival after surgical management of neuroendocrine hepatic metastases. HPB (Oxford) 2010;12:427–33.
   PubMed Web of Science ®Google Scholar
• Basuroy R, Srirajaskanthan R, Ramage JK. A multimodal approach to the management of neuroendocrine tumour liver metastases. Int J Hepatol 2012;2012:819193.
   PubMedGoogle Scholar
• Frilling A, Sotiropoulos GC, Li J, Kornasiewicz O, Plockinger U. Multimodal management of neuroendocrine liver metastases. HPB (Oxford) 2010;12:361–79.
   PubMed Web of Science ®Google Scholar
• Knigge U, Hansen CP, Stadil F. Interventional treatment of neuroendocrine liver metastases. Surgeon 2008;6:232–9.
   PubMed Web of Science ®Google Scholar
• Harring TR, Nguyen NT, Goss JA, O’Mahony CA. Treatment of liver metastases in patients with neuroendocrine tumors: A comprehensive review. Int J Hepatol 2011;2011:154541.
   PubMedGoogle Scholar